Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
NCT04061863
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
Nivolumab
Sponsor
Seoul National University Hospital
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]